期刊文献+

重组精氨酸脱亚胺酶的制备工艺

Study of Preparation Technology of Recombinant Arginine Deiminase
下载PDF
导出
摘要 研究了重组精氨酸脱亚胺酶(r ADIES)的30 L规模发酵、制备工艺及其生物学活性。将构建好的工程菌先进行摇瓶活化获得种子液,转入30 L发酵罐进行培养,用IPTG进行诱导表达;表达产物进行高压匀浆破菌、包涵体洗涤、溶解稀释复性后经DEAE阴离子交换层析柱和Butyl疏水层析柱纯化;通过SDS-PAGE和RP-HPLC等方法检测表达和纯度;用体外测活法检测活性。将工程菌进行放大培养并诱导表达,获得了相对分子质量在46 k Da的r ADIES。重组蛋白表达量占总蛋白的25%以上,经制备工艺获得的r ADIES纯度高于95%,酶活性为42IU。实验结果表明:该工艺具有可行性,可以获得较高活性的重组精氨酸脱亚胺酶。 The 30 L scale fermentation, preparation technology and biological activities of recombinant arginine deiminase (rADI-ES) were investigated. The seed solution was obtained by shaking flask activation of the constructed engineering bacteria, and then transferred it to 30 L fermenter for enlarging cultivation, and IFFG was used for its induction expression. The expression products broke bacterium by high-pressure homogenizer, and inclusion bodies were washed by buffer, and after dissolved refolding, the product was purified with DEAE anion exchange chromatography and Butyl hydrophobic interaction chromatography column, and we detected its expression and purity by SDS-PAGE and RP-HPLC analysis. The activity of rADI-ES was determined in vitro. We successfully amplified and induced expression of the engineering bacteria, and obtained the rADIES with the molecular weight of 46 kDa. The expression quantity of recombinant protein counts about more than 25 % total protein, and the purity of the purified rADI-ES is more than 95 % and its enzymatic activity is 42 IU. The expeiment show that the process is feasible to obtain a higher purity and activity of recombinant arginine deiminase.
出处 《重庆理工大学学报(自然科学)》 CAS 2016年第4期73-78,共6页 Journal of Chongqing University of Technology:Natural Science
关键词 精氨酸脱亚胺酶 发酵 复性 分离纯化 arginine deiminase fermentation refold purification
  • 相关文献

参考文献14

  • 1GILBERT C S,MILAN A L,ALFRED A T. The degrada- tion of arginine by Clostridium perfringens (BP6K) [ J ]. Journal of Biological Chemisty, 1952,198 ( 2 ) :771-783.
  • 2KNODLER L A, SCHOFIELD P J, EDWARDS M R. Larginine transport and metabolism in Giardia intestinalis support its position as a transition between the prokaryot- ic and eukaryotic kingdoms [ J]. Microbiology, 1995,141 (5) :2063-2070.
  • 3SYED N,LANGER J,JANCZAR K,et al. Epigenetic sta- tus of argininosuccinate synthetase and argininosuecinate lyase modulates autophagy and cell death in glioblastoma [ J]. Cell Death Dis,2013,4( 1 ) :e458.
  • 4ENSOR C M, HOLTSBERG F W, BOMALASKI J S, et al. Pegylated arginine deiminase (ADI-SS PEG20, 000mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo[ J ]. Cancer Res,2002,62 (19) :5443-5450.
  • 5DILLON B J,PRIETO V G, CURLEY S A, et al. Inci- dence and distribution of argininosuccinate synthetase de- ficiency in human eaneers:a method for identifying canc- ers sensitive to arginine deprivation [ J ]. Cancer, 2004, 100(4) :826-833.
  • 6ANNA S,TERESA S,ELZBIETA A. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials [ J ]. Expert Opinion on Investigational Drugs ,2014,23 ( 11 ) : 1517-1529.
  • 7ATKAN F. iNOS-mediated nitric oxide production and its regulation [ J ]. Life Sei ,2004,75 ( 6 ) :639-653.
  • 8GONG H,ZLZER F, yon RECKLINGHAUSEN G, et al. Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis [ J ]. Biochem Biophys Res CommoL/Lun, 1999,261 ( 1 ) : 10-14.
  • 9KIM J E,JEONG D W,LEE H J. Expression,purification and characterization of arginine deiminase from Lactoeoc-cus lactis ssp. lactis ATCC 7962 in Escherichia eoli BI21 [J]. Protein Expr Purif,2007,53 (1) :9-15.
  • 10魏星,苏勇,张加慧.精氨酸脱亚胺酶的克隆表达和纯化[J].世界临床药物,2013,34(5):280-284. 被引量:1

二级参考文献32

  • 1张成长.罗荣城:应用靶向治疗完成带瘤生存[J].中国健康月刊,2007(5):30-31. 被引量:1
  • 2钱嘉南,孙志浩,刘宇鹏,孟繁君,刘咏梅.二乙酰一肟-氨基硫脲比色法测定酶转化液中的L-瓜氨酸[J].中国医药工业杂志,2007,38(7):519-522. 被引量:18
  • 3Verhoef C, Visser O, de Man RA, et al. Hepatocellular carcinoma in the Netherlands incidence, treatment and survival patterns [J]. European Journal of Cancer, 2004, 40: 1530-- 1538.
  • 4El-Scrag H B, Mason A C, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States [J]. Hepatology, 2001, 33: 62--65.
  • 5El-Serag HB. Hepatocellular carcinoma: an epidemiologic view[J]. Clin Gastroenterol, 2002, 35:S72--S78.
  • 6Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase Ⅰ/Ⅱ studies[J]. J Clin Oncol, 2004,22(10) :815--822.
  • 7Takaku H, Takase M, Miyazaki K, et al. In vivo anti tumor activity of arginine deiminase purified from Mycoplasma arginini[J], Int J Cancer, 1992, 51: 244-249.
  • 8Takaku H, Misawa S, Hayashi H, et al. Chemical modification by polyethylene glycol of the anti--tumor enzyme argi- nine deiminase from Mycoplasma arginini[J]. Jpn J Cancer Res, 1993, 84: 1195--1200.
  • 9Takaku H, Matsumoto M, Misawa S, et al. Anti-tumor activity of arginine deiminase from Mycoplasma arginini and its growth inhibitory mechanism[J]. Jpn J Cancer lies, 1995, 86: 840--846.
  • 10Miyazaki K, Takaku H, Umeda M, et al. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line[J]. Cancer Res, 1990, 50: 4522--4527.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部